Thanks for the chart of possible uses for rATIII in different acquired deficiences. When the partnership finally does materialize, I would like to see them fully fund trials in one or more of them. The point is we need to expand rATIII past only sepsis since I don't know if GTCB could survive if the sepsis news is bad.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.